Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: Retrospective US cohort study

被引：0
|
作者：
Simmons, Daniel [1 ]
Blank, Stephanie [2 ]
Nagar, Saurabh [3 ]
Nham, Tram [3 ]
Long, Grainne [4 ]
Davis, Keith [3 ]
Wetherill, Graham [4 ]
Munley, Jiefen [4 ]
McLaurin, Kimmie [4 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Icahn Sch Med, Blavatnik Family Womens Hlth Res Inst, New York, NY USA
[3] RTI Hlth Solut, Durham, NC USA
[4] AstraZeneca Pharmaceut LP, Cambridge, England
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.329
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2209
引用
收藏
页码：S262 / S263
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
    Kanaan, Saad
    Hettie, Gabrielle
    Loder, Elizabeth
    Burch, Rebecca
    [J]. CEPHALALGIA, 2020, 40 (13) : 1511 - 1522
  • [2] Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
    O'Malley, David M.
    Arend, Rebecca Christian
    Alam, Naufil
    Ozgoren, Ozan
    McLaurin, Kimmie K.
    Long, Grainne H.
    Banerjee, Susana N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] FIRST-LINE MAINTENANCE AMONG ADVANCED OVARIAN CANCER PATIENTS IN THE US ONCOLOGY NETWORK: A REAL-WORLD RETROSPECTIVE COHORT STUDY
    Chase, Dana
    Liu, Jinan
    Moore-Schiltz, Laura
    Perhanidis, Jennifer
    Bulsara, Purva
    Patton, Gregory
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A33 - A33
  • [4] REAL-WORLD OUTCOMES OF PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: A RETROSPECTIVE COHORT STUDY OF US ELECTRONIC HEALTH RECORDS
    Banerjee, S.
    Smith, G.
    Lima, J.
    Long, G.
    Alam, N.
    Nakamura, H.
    Meulendijks, D.
    Monk, B. J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A84 - A85
  • [5] Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records
    Monk, Bradley J.
    Smith, Gabriella
    Lima, Julianne
    Long, Grainne H.
    Alam, Naufil
    Nakamura, Hitomi
    Meulendijks, Didier
    Ghiorghiu, Dana
    Banerjee, Susana
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 325 - 332
  • [6] Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database
    Zheng, Peng
    Zheng, Ping
    Chen, Guilin
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [7] Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer
    Veljovich, Dan Steven
    Penson, Richard T.
    Birrer, Michael J.
    Luo, Linlin
    Pyrih, Nick
    Pack, Simon
    Iu, Crystal
    Hada, Manila
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China
    Chen, Jinghong
    Zhang, Mengpei
    Li, Kemin
    Duan, Yuanqiong
    Zeng, Jing
    Li, Qingli
    Wang, Danqing
    Song, Liang
    Li, Qintong
    Yin, Rutie
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer
    Beachler, Daniel C.
    Lamy, Francois-Xavier
    Russo, Leo
    Taylor, Devon H.
    Dinh, Jade
    Yin, Ruihua
    Jamal-Allial, Aziza
    Dychter, Samuel
    Lanes, Stephan
    Verpillat, Patrice
    [J]. JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [10] A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer
    Daniel C. Beachler
    Francois-Xavier Lamy
    Leo Russo
    Devon H. Taylor
    Jade Dinh
    Ruihua Yin
    Aziza Jamal-Allial
    Samuel Dychter
    Stephan Lanes
    Patrice Verpillat
    [J]. Journal of Ovarian Research, 13
12345